Inequities in people with gout: a focus on Māori (Indigenous People) of Aotearoa New Zealand.
gout
health disparity
health equity
Journal
Therapeutic advances in musculoskeletal disease
ISSN: 1759-720X
Titre abrégé: Ther Adv Musculoskelet Dis
Pays: England
ID NLM: 101517322
Informations de publication
Date de publication:
2021
2021
Historique:
received:
07
04
2021
accepted:
08
06
2021
entrez:
15
7
2021
pubmed:
16
7
2021
medline:
16
7
2021
Statut:
epublish
Résumé
Health equity can be defined as the absence of systematic disparities in health between more and less advantaged social groups. Gout is one of the most common forms of arthritis and disproportionally affects Indigenous peoples, including Māori in Aotearoa New Zealand. Inequities in gout management are well documented and clearly evidenced in Indigenous populations. For example, while gout occurs at a younger age and is more severe in Māori, there is less regular dispensing of urate-lowering therapies. Indigenous peoples are also under-represented in clinical trials. Herein, we will review inequities in gout using Aoteoaroa New Zealand as an example. We will explore reasons for health inequities and challenges that need to be faced to achieve health equity.
Identifiants
pubmed: 34262623
doi: 10.1177/1759720X211028007
pii: 10.1177_1759720X211028007
pmc: PMC8252336
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1759720X211028007Informations de copyright
© The Author(s), 2021.
Déclaration de conflit d'intérêts
Conflict of interest statement: LTK was supported for this work by the Health Research Council of New Zealand (Te Karu 19/078) ND reports grants and personal fees from AstraZeneca, grants from Amgen, personal fees from Dyve, Arthrosi, Selecta, Horizon, PK Med and JW Pharmaceutical Corporation, outside the submitted work.
Références
Rheum Dis Clin North Am. 2020 Nov;46(4):693-703
pubmed: 32981646
Curr Rheumatol Rep. 2011 Apr;13(2):154-9
pubmed: 21161617
Nat Genet. 2019 Oct;51(10):1459-1474
pubmed: 31578528
Health Policy. 2018 Aug;122(8):837-853
pubmed: 29961558
J Prim Health Care. 2013 Sep 01;5(3):214-22
pubmed: 23998172
Intern Med J. 2013 Jun;43(6):678-84
pubmed: 23279108
Soc Sci Med. 1985;20(5):483-6
pubmed: 3992288
Ann Rheum Dis. 2017 Jan;76(1):29-42
pubmed: 27457514
Arthritis Rheumatol. 2019 Oct;71(10):1739-1746
pubmed: 31081595
Hum Mol Genet. 2010 Dec 15;19(24):4813-9
pubmed: 20858603
Ann Rheum Dis. 2016 Jan;75(1):124-30
pubmed: 25187157
Arthritis Res Ther. 2017 Mar 7;19(1):43
pubmed: 28270222
Arthritis Rheumatol. 2017 Jul;69(7):1461-1469
pubmed: 28371506
BMC Med Res Methodol. 2019 Aug 9;19(1):173
pubmed: 31399058
J Prim Health Care. 2021 Mar;13(1):27-35
pubmed: 33785108
Clin Rheumatol. 2013 Feb;32(2):247-51
pubmed: 23114632
Rheumatology (Oxford). 2012 Oct;51(10):1820-4
pubmed: 22723595
Glob Health Promot. 2015 Mar;22(1):21-31
pubmed: 24842989
Ann Rheum Dis. 2012 Nov;71(11):1765-70
pubmed: 22863577
Int J Equity Health. 2017 Feb 21;16(1):26
pubmed: 28219429
J Epidemiol Community Health. 2003 Apr;57(4):254-8
pubmed: 12646539
Int J Equity Health. 2019 Jan 7;18(1):3
pubmed: 30612567
J Chronic Dis. 1981;34(2-3):65-75
pubmed: 7462382
N Z Med J. 2018 Nov 9;131(1485):8-12
pubmed: 30408813
Global Health. 2017 Sep 5;13(1):69
pubmed: 28870225
Lancet. 2016 Jul 9;388(10040):131-57
pubmed: 27108232
Lancet. 2018 Oct 20;392(10156):1403-1412
pubmed: 30343856
J Prim Health Care. 2018 Mar;10(1):11-15
pubmed: 30068445
Arthritis Rheumatol. 2017 Sep;69(9):1903-1913
pubmed: 28597604
Cancer. 2020 Jan 1;126(9):1958-1968
pubmed: 32147815